Author

Anna E. Vilgelm

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteORCID 0000-0002-4446-913XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:organoid / primary culture· 1

Frequent Co-Authors

Vijaya BhartiiD· 2 shared Aharon G. FreudiD· 1 shared Aleksander SkardaliD· 1 shared Alexander E. DaviesiD· 1 shared Arjun MittraiD· 1 shared Bridget A. OppongiD· 1 shared Connor Durham· 1 shared Dean A Lee· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Vijaya BhartiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintApr 22, 2026

CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteins

Yinchong Wang, Evdokiya Reshetnikova, Nar Bahadur Katuwal…·Anna E. Vilgelm

This paper shows CDK4/6 inhibitors make breast cancer cells more susceptible to NK cell therapy by increasing surface proteins that NK cells recognize.

DOI 10.64898/2026.04.19.719504

humanorganoid / primary culture

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJul 9, 2025

Evaluation of natural killer cell tumor homing and effector function in response to CDK4/6 and AURKA inhibition in a melanoma tumor-on-a-chip platform

Srija Chakraborty, Connor Durham, Vijaya Bharti…·Aleksander Skardal

This study evaluates how CDK4/6 and AURKA inhibition enhances NK cell homing and tumor-killing in melanoma models using tumor-on-a-chip platforms.

2 citations

humanexperimental assay

𝕏 PostBluesky